Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice

Rong Jin, MD, PhD*; Xiaolei Zhu, MD, PhD*; Lin Liu, MD, PhD; Anil Nanda, MD; D. Neil Granger, PhD; Guohong Li, MD, PhD

Background and Purpose—Statins are widely used in the primary and secondary prevention of ischemic stroke, but their effects on stroke-induced immunodeficiency and poststroke infections are elusive. We investigated the effects of simvastatin treatment on stroke-induced splenic atrophy and lung susceptibility to bacterial infection in acute experimental stroke in mice.

Methods—Ischemic stroke was induced by transient middle cerebral artery occlusion, followed by reperfusion. In some experiments, splenectomies were performed 2 weeks before middle cerebral artery occlusion. Animals were randomly assigned to sham and middle cerebral artery occlusion groups treated subcutaneously with vehicle or simvastatin (20 mg/kg per day). Brain infarction, neurological function, brain interferon-γ expression, splenic atrophy and apoptosis, and lung infection were examined.

Results—Simvastatin reduced stroke-induced spleen atrophy and splenic apoptosis via increased mitochondrial antiapoptotic Bcl-2 expression and decreased proapoptotic Bax translocation from cytosol into mitochondria. Splenectomy reduced brain interferon-γ (3 days) and infarct size (5 days) after stroke, and these effects were reversed by adoptive transfer of splenocytes. Simvastatin inhibited brain interferon-γ (3 days) and reduced infarct volume and neurological deficits (5 days) after stroke, and these protective effects were observed not only in naive stroke mice but also in splenectomized stroke mice adoptively transferred with splenocytes. Simvastatin also decreased the stroke-associated lung susceptibility to spontaneous bacterial infection.

Conclusions—Results provide the first direct experimental evidence that simvastatin ameliorates stroke-induced peripheral immunodeficiency by attenuating spleen atrophy and lung bacterial infection. These findings contribute to a better understanding of the beneficial effects of statins in the treatment of stroke. (Stroke. 2013;44:1135-1143.)

Key Words: bacterial infection ■ brain ischemia ■ immune response ■ statin ■ spleen

Stroke is the third leading cause of death in the world, but treatment options for acute stroke remain limited. Cerebral ischemia not only produces local brain damage but also triggers a profound systemic immunodeficiency or stroke-induced immunodeficiency syndrome, which predisposes patients after stroke to infections.1-3 Infectious complications, predominantly chest and urinary tract infections, occur in many stroke patients within the first few days after stroke and are a leading cause of death in patients with acute stroke.4,5 The prognosis of stroke depends strongly on the incidence of infectious complications, in particular pneumonia. Pneumonia is the most common poststroke infection, about half of pneumonia cases occur within the first 2 days after stroke onset, and almost all cases occur within the first week.6 Thus, therapeutic modification of poststroke immunodeficiency and avoiding poststroke infections may represent a valuable approach to improving outcome in stroke patients.6 Statins are inhibitors of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A, and they are the most effective agents for lowering cholesterol in clinical practice for the treatment of cardiovascular diseases. Recently, it has become clear that statins also have pleiotropic effects on inflammation and immunity in addition to their lipid-lowering properties.7 Previous studies have reported that statins have beneficial effects on various forms of experimental brain injury, such as ischemic stroke,8,9 subarachnoid hemorrhage,10 and intracerebral hemorrhage.11,12 Statins are widely used in the primary and secondary prevention of ischemic stroke.
poststroke peripheral immunodepression is characterized by profound atrophy of secondary lymphatic organs (spleen, thymus, and lymph node) that occur within the first few days after stroke. Several recent studies have reported that spleen contributes to neuroinflammation and the development of ischemic stroke in acute experimental stroke. Splenectomy 2 weeks before middle cerebral artery occlusion (MCAO) in the rat significantly reduces neuroinflammation and brain damage.

To our knowledge, no experimental studies have addressed if and how statins affect stroke-induced immunodepression and poststroke infections. Thus, the present study was designed to investigate the effects of simvastatin on stroke-induced peripheral immunodepression and poststroke infections. We focused on the investigation of the effects of simvastatin on stroke-induced splenic atrophy and lung susceptibility to bacterial infection.

**Methods**

**Ethics Statement**

All experimental procedures were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and approved by the Animal Care and Use Committee of the Louisiana State University Health Science Center-Shreveport (IACUC Approval number: 11010). Male C57BL/6J mice (8–10 weeks old, 22–25 g), obtained from Jackson Laboratories (Bar Harbor, ME), were used in the study.

**Experimental Model of Stroke**

Focal cerebral ischemia was induced by transient occlusion of the left MCAO with a 6-0 silicone-coated nylon monofilament (Doccol Corp), as previously described. Subgroups of mice were randomly selected to receive MCAO or sham procedures. In ischemic groups, animals were subjected to 60 minutes of MCAO followed by reperfusion for indicated times. In the sham controls, the arteries were visualized but not disturbed. Rectal temperature was maintained at 37±0.5°C throughout the procedure from the start of the surgery until the animals recovered from anesthesia with a feedback-regulated heating pad. Regional cerebral blood flow was monitored by laser Doppler flowmetry (MSP300XP; ADInstruments Inc), as previously described. Only animals that exhibited a reduction in cerebral blood flow >85% during MCAO and a cerebral blood flow recovery >80% after 15 minutes of reperfusion were included in the study.

**Splenectomy and Adoptive Transfer of Splenocytes**

In some experiments, splenectomy was performed 2 weeks before MCAO using the published procedure. Briefly, under anesthesia a left flank skin incision (=2.5 cm long) was made and the spleen was exposed and pulled onto the exterior surface of the peritoneum with blunt forceps. The splenic blood vessels were tied off with sutures and the spleen was removed. The abdominal wall and skin incision were closed with sutures. Sham operations were also performed where the spleen was exteriorized and then reinserted into the abdominal cavity.

Splenocytes were prepared from spleens of male wild-type mice by forcing the tissues through a fine wire mesh. Cells were washed and resuspended in 2 mL of Dulbecco’s PBS containing 10% fetal calf serum, 2 mmol/L glutamine, and 100 μg/mL of streptomycin and penicillin, and contaminating erythrocytes were lysed using 1X red cell lysis buffer (BD Biosciences). One hour after MCAO, isolated splenocytes (2×10^7 in 250 μL PBS) or equal volume of PBS was infused (3 minutes) into splenectomized or sham-splenectomized mice via the femoral vein.

**Drug Administration**

Simvastatin (Sigma Chemicals) was prepared as a 5 mg/mL stock, as previously described. Briefly, 5 mg of simvastatin was dissolved in 100 μL of ethanol and 150 μL of 0.1 N NaOH, incubated at 50°C for 2 hours, then added water to 800 μL volume and the pH adjusted to 7 with 1 N HCl, and the final volume corrected to 1 mL. This simvastatin stock solution was stored at −80°C and diluted with sterile saline immediately before use. Animals were randomized to receive subcutaneous injection of simvastatin 20 mg/kg per day or saline treatment for 5 days, with the first dose given immediately after MCAO. The doses of statin chosen are consistent with the primary bioactive dose used in vivo in mouse/rodent studies (typically 10–100 mg/kg per day).

**Brain Infarct Measurement**

On day 5 after MCAO, the mice were euthanized by deep anesthesia and then perfused transcardially with 30 mL of PBS followed by cold 4% paraformaldehyde in PBS. The brains were collected and incubated overnight in the 4% paraformaldehyde solution and then transferred into 10%, 20%, and 30% sucrose solution until they sank. Then, coronal sections (40-μm thick) were serially cut using a cryostat, starting from the frontal pole through the entire brain, and 5 coronal sections at 1 mm intervals (relative to bregma: +1, 0, −1, −2, −3 mm) were selected and stained with 0.1% crystal violet solution (pH 3.8) for 5 minutes. The areas of the uncorrected infarcted area and the total areas of both hemispheres were measured for each slice by a computerized National Institutes of Health image analysis system. Corrected infarct area in a slice was calculated by subtracting the area of normal tissue in the ipsilateral hemisphere from the total area of the contralateral hemisphere. Total corrected infarct volume was then calculated by multiplying the area by the slice thickness and summing the volumes from all slices. All measurements were performed by 2 blinded researchers, and the mean of their results was calculated.

**Neurological Scoring**

The neurological scores were assessed by a 28-point neurological score test by an experimenter blinded to the experimental groups at 1, 3, and 5 days. Scoring was based on physical appearance and behavior using a scale previously developed to provide a precise assessment of focal neurological damage. The mice were scored in each of the following 7 categories: body symmetry, gait, climbing, circling behavior, forelimb symmetry, compulsory circling, and sensory response. Each mouse was scored from 0 (no deficit) to 4 (severely affected) in each category, as previously described.

**Detection of Stroke-induced Splenocyte Apoptosis**

Fresh spleens from sham-operated and MCAO mice were collected, and whole splenocytes were obtained by gentle grinding of spleens between frosted glass slides. The erythrocytes were lysed with a BD Pharm Lyse Lysing Buffer (Cat. No. 555899), and single cell suspensions were collected by passing the tissue through a 100-μm nylon mesh. Collected splenocytes were washed twice in PBS, counted, and reconstituted in Ca²⁺-rich annexin V binding buffer (BD Pharmingen) at a concentration of 10^7 cells/mL. Cell suspension (100 μL) was stained with 2.5 μL annexin V-fluorescein isothiocyanate and 1 μL propidium iodine (PI) for 15 minutes and adjusted to a total volume of 500 μL with binding buffer. Cells were then analyzed by flow cytometry with FACSCalibur (BD Biosciences), and annexin V+/PI− cells were considered as apoptotic cells. The percentage of apoptotic cells was calculated according to total annexin V/PI− divided by total cells.
Analysis of THC-induced Splenocyte Apoptosis In Vitro

Fresh spleen cells were isolated from C57BL/6 mice as described above. Tetrahydrocannabinol (THC)-induced apoptosis in splenocytes was analyzed as described previously. A single cell suspension in complete medium (Roswell Park Memorial Institute (RPMI) 1640 medium [Sigma] supplemented with 5% fetal bovine serum, 10 mmol/L HEPES, 1 mmol/L glutamine, 40 μg/mL gentamicin sulfate, and 50 μmol/L 2-mercaptoethanol) was added to 24-well flat bottom plates (1×10^6 cells/well) and treated without or with simvastatin (25 μmol/L) for 1 hour, followed by 10 μmol/L A-9-THC (Sigma) for additional 16 hours. After that, the cells were harvested and washed twice with PBS/0.2% BSA and stained with annexin V-fluorescein and PI for flow cytometry analysis.

Western Blot Analysis

Mice were transcardially perfused with ice-cold PBS, and spleens were removed and splenocytes isolated as described above. The cytosolic and mitochondrial fractions were prepared from the isolated splenocytes using a commercially available cytosol/mitochondria fractionation kit according to the manufacturer’s protocol (Millipore). Samples were stored at −80°C for further analysis. Antibodies were used as follows: monoclonal rabbit antibody against Bcl-2 (1:1000), Bax (1:1000), COX-V (1:1000) (all purchased from Cell Signaling), and mouse antibody against β-actin (Sigma). Immunopositive bands of horseradish peroxidase–conjugated secondary antibodies were detected with an ECL system (GE Healthcare) and by exposure to ECL Hyperfilm.

ELISA

Mice were transcardially perfused with ice-cold PBS, and the ipsilateral cerebral cortex was collected and immediately homogenized in 5 volumes of PBS with complete protease cocktail (Roche, Indianapolis, IN) using a dounce homogenizer. After incubation on ice for 5 minutes, the extracts were cleared by centrifugation at 20,800 x g (14000 rpm) for 10 minutes. The protein content of each extract was determined by the Bradford protein assay (Bio-Rad). ELISA assays were performed using Mouse IFN-γ ELISA kit (Thermo scientific, Rockford, IL) following the manufacturer’s instructions.

Statistical Analysis

Variables were analyzed by Student t test (2-tailed), and a P<0.05 was considered statistically significant. Values are expressed as mean±SD of at least 3 independent experiments. Animal survival rates between the groups were analyzed using the log-rank test.

Results

Simvastatin Attenuates Stroke-induced Splenic Atrophy and Body Weight Loss

Splenic atrophy is an important feature of stroke-induced peripheral immunodepression and is characterized by reduced organ size and reduced number of spleen cells that occurred within the first few days after a stroke. The spleen weight and the number of splenocytes in vehicle-treated groups were significantly decreased at 3 and 5 days after MCAO compared with sham controls (Figure 1A and 1B). The reduction and regain of body weight were measured as an index of general stress elicited by cerebral ischemia. In vehicle-treated animals, body weight was significantly decreased at 1 day and continued to decrease 5 days after MCAO (Figure 1C). Simvastatin treatment significantly attenuated the splenic atrophy and body weight loss within the 5-day observation period (Figure 1A–1C).

Simvastatin Inhibits Splenocyte Apoptosis Through Mitochondrial Pathway

Induction of apoptosis is one of the mechanisms leading to splenic atrophy in experimental stroke. Previous studies with mice have shown that splenocyte apoptosis was significantly induced as early as 12 hours after transient MCAO, and the apoptosis was further increased over time (22–96 hours) after stroke. Thus, we investigated whether simvastatin reduced spleen atrophy through inhibition of splenocyte apoptosis at both the early (12 hours) and late (5 days) time points after MCAO. Flow cytometry analysis was performed to identify and quantify splenocyte apoptosis. Annexin V+ PI− cells are considered apoptotic cells. The number of annexin V+ PI− apoptotic cells from the spleens of the vehicle-treated mice was significantly increased at 12 hours and further increased at 5 days after MCAO, but this increase at both time points was significantly inhibited by simvastatin treatment (Figure 2A and 2B). Furthermore, we determined whether simvastatin can directly act on spleen cells in vitro. The apoptosis of splenocytes isolated from C57Bl5 mice was induced by A-9-THC, a well-known immunosuppressive agent. Treatment with THC (10 μmol/L for 16 hours) significantly increased apoptosis of splenocytes (Figure 2C and 2D), consistent with published data. Clearly, simvastatin significantly decreased THC-induced spleen cell apoptosis in vitro (Figure 2C and 2D).

Furthermore, we examined the molecular mechanisms underlying the simvastatin-mediated antiapoptotic effects. The ratio of proapoptotic Bax to antiapoptotic Bcl-2 proteins is considered a major checkpoint in apoptosis. The membrane and cytosolic fractions of the spleen cells were prepared from the sham or MCAO mice treated with vehicle or simvastatin, and the fractions were analyzed by Western blotting to measure the expression levels of these apoptosis regulatory proteins.
proteins. The expression of Bcl-2 protein in mitochondria was markedly reduced in the vehicle-treated group, but this reduction was largely reversed in the simvastatin-treated group (Figure 2E). Bax is mostly cytosolic and translocates to mitochondria after an apoptotic stimulus. The expression of Bax was significantly decreased in the cytosol by a concomitant increase in the mitochondria of the spleens from the vehicle-treated stroke group, but these changes were reversed by simvastatin treatment (Figure 2E).

Simvastatin Reduces Brain IFN\(\gamma\) Expression and Brain Injury Contributed by Splenocytes

We performed splenectomy or sham operation 2 weeks before MCAO in C57Bl6 mice. The mean total infarct volume (5 days) was 30.6±7.9 mm\(^3\) in splenectomized animals and 54.7±7.0 mm\(^3\) in sham controls (\(P<0.01\); Figure 3A). The 28-point neurological score (3, 5 days) was also improved in splenectomized animals (Figure 3B) compared with sham controls. Furthermore, we demonstrated that adoptive transfer of isolated splenocytes into splenectomized mice abolished the stroke-protective effects of splenectomy on infarct volumes (Figure 3A) and neurological score (Figure 3B). These data established a role of spleen in a mouse stroke model. Furthermore, simvastatin treatment significantly decreased infarct volume (39.5±5.9 mm\(^3\); Figure 3A) and improved neurological score (Figure 3B) in splenectomized mice adoptively transferred with splenocytes. In addition, we observed that simvastatin treatment and splenectomy did not significantly alter regional cerebral blood flow (Figure I in the online-only Data Supplement) and blood physiological parameters (Table I in the online-only Data Supplement).

Next, we examined if and how simvastatin affects the interferon (IFN)-\(\gamma\) protein expression in the brain at 72 hours after MCAO. This time point was chosen based on the published data showing that IFN\(\gamma\) protein levels were increased in the brain most prominently at 72 hours after MCAO in rats.\(^{17}\) We demonstrated that IFN\(\gamma\) protein levels were increased in the brain of sham-splenectomied MCAO mice, but the increase was abolished in splenectomized MCAO mice (Figure 3C). Furthermore, the IFN\(\gamma\) protein levels in the brain of splenectomized MCAO mice were regained by adoptive transfer of isolated splenocytes (Figure 3C), and this was largely abolished by simvastatin treatment (Figure 3C). In addition, simvastatin treatment significantly reduced the IFN\(\gamma\) protein levels in the brain of MCAO mice without a splenectomy or sham-splenectomy (Figure 3D). Collectively, these data suggest that simvastatin protects the brain against ischemic injury contributed by spleen cells through modulating brain IFN\(\gamma\) expression.

Simvastatin Reduces Brain Damage and Mortality in Acute Experimental Stroke

Previous work showed that simvastatin pretreatment reduced brain injury at early time point (24 hours) after transient MCAO in mice.\(^ {14}\) We further determined whether simvastatin protects brain against ischemic injury at a later time point after stroke. Brain infarction at 5 days after MCAO was measured on cresyl violet–stained coronal sections. Animal survival rate from the same experimental groups was evaluated daily.
Figure 2. Simvastatin attenuates splenocyte apoptosis through mitochondrial pathway. A and B, Mice were euthanized 12 hours or 5 days after middle cerebral artery occlusion (MCAO) for splenic analysis. A, Representative flow cytometric dot plots for fluorescein isothiocyanate (FITC)-annexin V and propidium iodide (PI) labeling in freshly isolated splenocytes from sham control mice and MCAO mice treated with vehicle or simvastatin. Annexin V+ and PI− cells were considered early apoptotic cells (lower right quadrant). B, Flow cytometric analysis of stroke-induced splenocyte apoptosis in the simvastatin- and vehicle-treated mice at the indicated time points after MCAO. The percentage of apoptotic cells was calculated from the ratio of apoptotic cells to total cells counted. Data represent the mean±SD of 4 independent experiments. #P<0.05 vs sham control; *P<0.05 vs vehicle control.

C, Representative flow cytometric dot plots showing tetrahydrocannabinol (THC)-induced splenocyte apoptosis in vitro. D, Flow cytometric analysis of THC-induced splenocyte apoptosis in vitro. Data represent the mean±SD of 5 independent experiments. #P<0.05 vs vehicle; *P<0.05 vs the THC-only group.

E, Western blot analysis of the protein levels of mitochondrial Bcl-2 and mitochondrial and cytosolic Bax in the splenic cells from sham control mice and MCAO mice treated with vehicle or simvastatin. β-actin and COX IV were used as loading controls for cytosolic and mitochondrial fractions, respectively. Data are presented as mean±SD of 4 independent experiments (n=4 mice/group for each experiment). *P<0.05, **P<0.01 vs sham control; #P<0.05 vs vehicle control.
in the 5-day observation period. The infarct volume (5 days) was 40.3±10.1 mm³ in the simvastatin-treated animals and 53.2±9.3 mm³ in vehicle-treated controls (*P<0.05; Figure 4A). The 28-point neurological score (1, 3, 5 days) was also significantly reduced in the simvastatin-treated animals (Figure 4B) compared with vehicle-treated controls. Impressively, all experimental mice (n=9) survived in the simvastatin-treated stroke group, whereas only 7 of 13 (53.8%) mice survived in the vehicle-treated stroke group during the 5-day observation period (*P<0.05; Figure 4C).

**Simvastatin Reduces Lung Susceptibility to Spontaneous Bacterial Infection After Stroke**

Histological examination revealed typical signs of bacterial pneumonia, showing lung consolidation, thickened alveolar septa, and intra-alveolar inflammatory infiltrates,33 in the vehicle-treated stroke mice at 72 hours after MCAO, but the damage to lung tissue was significantly attenuated in the simvastatin-treated stroke (n=5 per group; Figure 5A). Furthermore, lung sections of sham controls revealed no signs of pneumonia (n=4; Figure 5A). Therefore, susceptibility to infection resulted from stroke but not from surgical stress. In addition, splenectomy did not increase lung susceptibility to bacterial infection 72 hours after MCAO (Figure II in the online-only Data Supplement).

Microbiological analysis revealed significant bacterial loads in lung cultures of all stroke mice at 24 and 72 hours after MCAO (Figure 5B). By examining bacteria grown on blood agar plates, we observed that bacterial cultures from lungs exhibited >95% gram-negative *Escherichia coli*, consistent with other reports.31 In contrast, lung cultures from sham-operated mice remained sterile at 72 hours (Figure 5B). In addition, no bacterial growth was observed in the blood cultures of either sham or MCAO mice, consistent with previous reports in C57Bl6 mice.31,34 Simvastatin significantly reduces bacterial growth in the lung tissue cultures (Figure 5B). These data suggest that simvastatin attenuates stroke-induced lung susceptibility to bacterial infection.

**Discussion**

Stroke-induced peripheral immunodepression occurs mostly during the first few days after acute stroke and involves
may contribute to brain injury possibly through (1) release of inflammatory mediators and (2) release of spleen-derived inflammatory cells into circulation and migration into the brain, which exacerbate the brain inflammatory response and cause secondary brain damage. In accordance with this concept, splenectomy has been shown to have beneficial effects in animal models of ischemic stroke, hemorrhagic stroke, and traumatic brain injury. The present data demonstrated that splenectomy 2 weeks before MCAO in mice significantly reduces infarct volume and neurological deficits 5 days after stroke. Furthermore, the stroke-protective effect of splenectomy was abolished by adoptive transfer of splenocytes. These results indicate that spleen substantially contributes to brain injury in the mouse stroke model used in the present study. The inflammatory signals from the spleen to the ischemic brain have not been completely identified. Our previous data suggest that IFN-γ plays an important role in acute experimental stroke, because IFN-γ knockout mice show reduced infarct volume after transient MCAO. Several studies suggest that IFN-γ could play a role in the splenic response by exacerbating the inflammation associated with ischemic brain injury. Recently, Seifert et al. reported that IFN-γ was elevated early (24 hours) in spleens but later (72, 96 hours) in the brains of rats after MCAO, and the neuroprotection of splenectomy is most likely caused by the loss of IFN-γ, because splenectomy reduced IFN-γ expression in the brain after MCAO and systemic administration of IFN-γ reversed the protective effects of splenectomy. Furthermore, intraventricular administration of IFN-γ-neutralizing antibodies 3 days after MCAO protects the brain from stroke-induced injury. Collectively, these findings indicate that IFN-γ may be one of the inflammatory signals originating from the spleen causing a delayed inflammatory response in the ischemic brain, supporting a role for spleen-derived IFN-γ in stroke pathology. In this regard, the present study focused on investigating stroke-induced IFN-γ expression in the brain and its modulation by adoptive transfer of splenocytes and by simvastatin treatment. The present data suggest that stroke-induced IFN-γ expression in the brain is associated with the splenic response to cerebral ischemia. Simvastatin treatment reduced brain IFN-γ (3 days) and infarct volume and neurological deficits (5 days) in acute experimental stroke, with a significant increase in animal survival during a 5-day period of observation. These protective effects by simvastatin were observed not only in naive MCAO stroke mice but also in splenectomied MCAO mice adoptively transferred with splenocytes. These findings support the hypothesis that the splenic response to cerebral ischemia contributes to secondary brain injury and simvastatin attenuates ischemic brain injury contributed by spleen cells via modulating IFN-γ expression in the brain in acute experimental stroke. Immunodepression after stroke increases the susceptibility to infections, in particular pneumonia, the most relevant complication in stroke patients. In addition to cholesterol-lowering effects, statins have anti-inflammatory and immunomodulatory properties, so called pleiotropic effects. Despite the existence of some controversies, the treatment of patients with statins has been shown to improve both incidence and survival in acute ischemic stroke. A recent clinical study

Figure 4. Simvastatin reduces ischemic brain injury and animal mortality 5 days after middle cerebral artery occlusion (MCAO). A, Representative images of cresyl violet–stained coronal brain sections (left) and quantitative analysis of infarct volumes (right). Scale bar, 2 mm. B, The 28-point neurological scoring at indicated time points in the vehicle-treated and simvastatin-treated mice (n=7–9 per group). *P<0.05 vs vehicle-treated group at the same time point. C, Animal survival rate from the same experiments was recorded daily for 5 days after MCAO (n=9 for simvastatin-treated and n=13 for vehicle-treated mice). *P<0.05, log-rank test compared with vehicle-treated mice.
shows that young patients with a first ischemic stroke who used statin poststroke had lower rates of new vascular events in a long-term follow-up. However, whether statins can help to prevent stroke-induced infections is still debated in clinical practice. Bacterial pneumonia is the most common cause of death in patients suffering from acute stroke and occurs mostly within the first few days after stroke. In the present study, we analyzed the infection status of mice in the first 3 days after acute experimental stroke. In agreement with previous reports, the present data show that 60-minute MCAO resulted in no bacterial growth in blood samples and bacterial growth in 100% of lung tissue cultures obtained from C57Bl6 mice. Notably, simvastatin treatment significantly inhibited the bacterial growth in the lung tissue cultures. It is worthy of note that the incidence of poststroke infections may vary largely depending on not only stroke models but also mouse strains. Liesz et al reported that mice with pure cortical infarcts in the coagulation model had no bacterial growth in blood and low-level bacterial growth in 30% of the lung tissue cultures; 30-minute MCAO resulted in no bacterial growth in blood samples and bacterial growth in 50% of lung tissue cultures. In contrast, 60% of the 90-minute MCAO mice had bacterial growth in blood cultures and 100% had growth in lung homogenates. Furthermore, Schulte-Herbrüggen et al reported that the susceptibility to poststroke infections in mice is strain dependent. They compared poststroke infections in mice from 129SV, C57/B6, and Balb/C strains subjected to a 60-minute MCAO. Three days after stroke, 129SV mice did not develop bacterial chest infection but also had a strongly increased susceptibility to bacteremia. In contrast, C57BL/6 and Balb/C mice acquired bacterial lung infections only, and these differences in susceptibility to infection did not correlate with infarct volumes. Therefore, careful interpretation of the results should be used when translating these experimental findings into clinical practice.

In summary, the results of the present study provide the first direct experimental evidence that simvastatin ameliorates stroke-induced peripheral immunodepression by attenuating spleen atrophy and lung bacterial infection. These findings contribute to a better understanding of beneficial effects of statins in the treatment of stroke and also may provide a rationale for future investigation of translational applicability for administration of simvastatin prophylactically and therapeutically using clinically relevant time windows of acute ischemic stroke. This study has some limitations, including no studies of comparisons of simvastatin’s effects with other statins, as well as the detailed mechanisms of how statins modulate immune response after ischemic stroke. Thus, further studies are needed.

**Sources of Funding**

This work was supported by National Institutes of Health grant HL087990 (Dr Li) and HL026441 (Dr Granger) and by a scientist development grant (0530166N, Dr Li) from the American Heart Association.

**Disclosures**

None.

**References**


Statin Attenuates Poststroke Immunodepression


Simvastatin Attenuates Stroke-induced Splenic Atrophy and Lung Susceptibility to Spontaneous Bacterial Infection in Mice

Rong Jin, Xiaolei Zhu, Lin Liu, Anil Nanda, D. Neil Granger and Guohong Li

Stroke. 2013;44:1135-1143; originally published online February 7, 2013;
doi: 10.1161/STROKEAHA.111.000633

Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/44/4/1135

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2013/02/07/STROKEAHA.111.000633.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
Supplemental data
Table S1. Splenectomy and simvastatin treatment did not significantly alter physiological parameters after MCAO
<table>
<thead>
<tr>
<th></th>
<th>MCAO</th>
<th>Simvastatin + MCAO</th>
<th>Splenectomy + MCAO</th>
</tr>
</thead>
<tbody>
<tr>
<td>MABP, mm Hg</td>
<td>95.7 ± 8.4</td>
<td>96.5 ± 7.5</td>
<td>94.6 ± 9.8</td>
</tr>
<tr>
<td>pO2, kPa</td>
<td>106 ± 32</td>
<td>109 ± 23</td>
<td>108 ± 23</td>
</tr>
<tr>
<td>pCO2, kPa</td>
<td>43.3 ± 4.8</td>
<td>43.2 ± 5.3</td>
<td>42.5 ± 8.5</td>
</tr>
<tr>
<td>pH</td>
<td>7.29 ± 0.46</td>
<td>7.31 ± 0.25</td>
<td>7.29 ± 0.45</td>
</tr>
</tbody>
</table>

MABP = Mean arterial blood pressure
Values are means ± SD.
Figure S1. Splenectomy and simvastatin treatment did not significantly alter regional cerebral blood flow (rCBF) after MCAO
Figure S1

- **MCAO+Vehicle**
- **MCAO+Simvastatin**
- **Splenectomy+MCAO**

rCBF (pre-ischemia %)

Time (min)

Reperfusion
Figure S2. Splenectomy did not increase stroke-induced lung susceptibility to spontaneous bacterial infection
Figure S2

CFU/ml (log 10)

MCAO

Splenectomy+MCAO

72h after MCAO

p=0.079

Figure S2
Table S1. Comparison of physiological parameters. During the experiments, blood pressure was monitored by Mouse Tail Cull Blood Pressure System (SC1000, Hatteras) and blood gas was measured using ABL5 blood gas analyzer 24h after MCAO. There were no significant differences between the indicated groups. n=8-10/group.

Figure S1. Comparison of regional cerebral blood flow (rCBF). rCBF was measured in the regions of ischemic core using a laser Doppler flowmeter as described previously (ref.1). No significant differences were observed between the indicated groups. n=8-10/group.

Figure S2. Splenectomy did not significantly increase lung susceptibility to spontaneous bacterial infection. 72h after MCAO, lungs samples from MCAO mice with or without splenectomy were prepared for bacteriological analysis. Data are expressed as CFU/ml (log 10) in lung tissue homogenate. n=4/group.

Reference